Work

Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988)

Year: 2020

Type: article

Source: Neurology

DOI: 10.1212/wnl.94.15_supplement.1988

Authors: Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell

Institutions: NYU Langone Health, New York University, Rocky Mountain Multiple Sclerosis Clinic, Biogen (United States), University of Alabama

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389447181

FWCI: 0.162

Cites:

Cited by: 2

Related to: 10